what this node claims
AlphaFold metrics / KDR
Model-quality receipt for the fold. It is not biological validation.
vertical proof spine
evidence / risk instrument
51%
low debt pressure
21%
71%structureusable
pLDDT 71.14
78%evidenceusable
grade B
0%gatesdebt
0/5 gates
100%riskstrong
0 hard flags
22%exportdebt
no export
33%lineagedebt
incomplete spine
proof completeness
33% missing target, candidate, finding, export- 01 target
- 02 fold
- 03 alphafold metric
- 04 candidate
- 05 finding
- 06 export
Metrics and receipt inputs
- confidence band
- confident
- confidence pct
- 71.14
- coverage context
- missing or not linked
- interpretation
- usable fold context with explicit model-confidence limits
- pae context
- missing or not linked
- plddt avg
- 71.14
- sequence length
- 0
AlphaFold metrics visual
Confident backbone model
1356 residues / min 24.44 / max 97.69 / source alphafold db
Very high
23.5%
318 residues / >=90
Confident
43.4%
589 residues / 70-89
Low
7.6%
103 residues / 50-69
Very low
25.5%
346 residues / <50
usable fold context with explicit model-confidence limits
Near-complete coverage / observed 1356 of 1356 residues.
- residues 1240-1356 / mean 32.49
- residues 1167-1236 / mean 32.26
- residues 937-999 / mean 31.96
- residues 785-822 / mean 39.87
proof debt register
21%
Visible limits, not hidden cleanup.
Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.